Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.

Digestion - 1 Jan 2010

Nichita Cristina, Stelle Marc, Vavricka Stephan, El-Wafa Ali Abdou, Ballabeni Pierluigi, de Saussure Philippe, Straumann Alex, Rogler Gerhard, Michetti Pierre

Abstract excerpt

BACKGROUND: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. AIM: To assess the long-term effectiveness and safet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Anti-Inflammatory Agents
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Crohn Disease

Share to Infliximab

Share to Logistic Models

Share to Switzerland

Source

Identifiers

PMID: 20093835
DOI: 10.1159/000253855

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20093835-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.PMID 20093835Read ↗

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.Semantic proximity Read ↗

Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practiceSemantic proximity Read ↗

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.Semantic proximity Read ↗

High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?Semantic proximity Read ↗

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three yearsSemantic proximity Read ↗

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read ↗

Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.Semantic proximity Read ↗

Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes.Semantic proximity Read ↗

5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.Semantic proximity Read ↗

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.Semantic proximity Read ↗

Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn's Disease.Semantic proximity Read ↗

Recent advances: Personalised use of current Crohn's disease therapeutic options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.